Research tools
Fecal calprotectin articles covering stool inflammation testing, flare monitoring, treatment response, and IBD research. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
Page 2 of 3 · 144 articles
Undernutrition and lean-mass loss are common and harmful in people with IBD. If dietary strategies can prevent weight and muscle loss and shift the gut microbiota toward SCFA producers, that could be relevant to...
This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...
Noninvasive fecal calprotectin levels tracked with endoscopic disease activity in children with colonic Crohn's disease, suggesting FC could help reduce repeat endoscopies and better monitor treatment response.
If confirmed, a pathology marker visible on routine biopsy (EGC patterns by SOX10 IHC) could help predict which children with ulcerative colitis are more likely to have improved mucosal inflammation over the first year,...
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost,...
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
People with suspected or known IBD and their clinicians want accurate, noninvasive tests to detect inflammation. This review suggests NGAL may be sensitive for identifying IBD but existing data are limited and uncertain,...
Children with newly diagnosed ulcerative colitis in this study commonly had reduced muscle mass (sarcopenia) at diagnosis, and the degree of muscle loss correlated with higher disease activity and inflammation....
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.
The study suggests FMT can clear mucosal adherent‑invasive E. coli (AIEC) in some people with Crohn’s disease and alters mucosal microbiome features linked to inflammation, which could be relevant to microbiome‑targeted...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...
Both EEN and the Crohn’s disease exclusion diet are used to induce remission in children with Crohn’s disease. Evidence that they perform similarly through 52 weeks may help families and clinicians choose the approach...
Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.
Physical activity may be a modifiable factor that could improve fitness, inflammation, symptoms like fatigue, and quality of life in children with IBD. This trial will provide objective, randomized data relevant to...
The study explores breath VOCs as a possible noninvasive biomarker for IBD activity, which could offer easier, more acceptable monitoring than colonoscopy or stool tests.
Distinguishing acute infectious gastroenteritis from new‑onset IBD can be clinically challenging. Faecal biomarkers that help tell these apart could speed correct diagnosis and treatment and avoid unnecessary...
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
Diet quality was linked to gut microbiome features and exploratory differences in inflammatory markers and symptoms in adults with Crohn disease from Puerto Rico; understanding these links may help tailor dietary...
Because having a sibling with Crohn's disease during childhood was linked to substantially higher risk of developing Crohn's later, and the study points to early-life microbiome differences and elevated faecal...
This trial tests whether a seaweed-derived fucoidan given with standard 5-ASA therapy can change biomarkers linked to mucosal healing (fecal calprotectin, fecal short-chain fatty acids) and stool consistency in people...
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
This trial tests a non-drug way (virtual reality medical-hypnosis content) to reduce pain and embarrassment during rectosigmoidoscopy — a common, sometimes poorly tolerated procedure in ulcerative colitis that patients...
A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.
The work aims to predict relapse and personalize herbal maintenance dosing for UC, which matters because better risk stratification and tailored management could reduce relapses and avoid unnecessary treatment changes.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
People with IBD and coexisting primary sclerosing cholangitis (PSC) may get faecal calprotectin tests to monitor colon inflammation. If PSC raises FC independently of colitis, FC could mislead decisions about IBD...
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...
Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...
Smoking and similar nicotine-product use after Crohn's surgery appears linked to higher rates of endoscopic recurrence, which may affect postoperative monitoring and secondary-prevention strategies. Patients using HNBT...
Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...
Sarcopenia (low muscle mass) was linked with worse outcomes in Crohn’s disease and, combined with fecal calprotectin and disease behaviour, formed a score that better predicted unfavourable courses. Identifying at-risk...
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
Fatigue is common and disabling for people with IBD; this study shows that factors beyond intestinal inflammation—especially central sensitization and psychological symptoms—explain much of fatigue. That means treating...
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
If confirmed, a brain perivascular/glymphatic change linked to intestinal inflammation could help explain why sleep problems are common in Crohn's disease and point to new research targets for symptom mechanisms and...
The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help...
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
Faecal calprotectin appears to be the best non‑invasive test among those studied for distinguishing UC from Crohn’s disease and for reflecting mucosal inflammation. Simpler blood‑based scores may help gauge systemic...
Noninvasive stool metabolite patterns could eventually help predict which people with Crohn’s disease are more likely to develop strictures or penetrating complications, and may offer markers of disease activity and...
Bowel wall vascularization on ultrasound is used to gauge transmural inflammation in Crohn’s disease. This study examines whether quantitative measures could make those assessments more objective and how technique and...
